Relevance of the MPTP primate model in the study of dyskinesia priming mechanisms
Authors:
- Frédéric CalonFCFrédéric Calon
- Marc MorissetteMMMarc Morissette
- Abdallah Hadj TaharATAbdallah Hadj Tahar
- Nancy BélangerNBNancy Bélanger
- Pershia SamadiPSPershia Samadi
- Richard GrondinRGRichard Grondin
- Laurent GrégoireLGLaurent Grégoire
- Leonard MeltzerLMLeonard Meltzer
- Thérèse Di PaoloTPThérèse Di Paolo
- Paul J BédardPBPaul J Bédard
- 1 July 2004
- journal article
- review article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 10 (5) , 297-304
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Increased striatal pre-proenkephalin B expression is associated with dyskinesia in Parkinson's diseaseExperimental Neurology, 2003
- Beginning‐of‐dose and rebound worsening in MPTP‐treated common marmosets treated with levodopaMovement Disorders, 2002
- μ- and δ-Opioid Receptor Antagonists Reduce Levodopa-Induced Dyskinesia in the MPTP-Lesioned Primate Model of Parkinson's DiseaseExperimental Neurology, 2001
- Control of glutamate release by calcium channels and κ‐opioid receptors in rodent and primate striatumBritish Journal of Pharmacology, 1999
- N‐0923, A novel soluble dopamine D2 agonist in the treatment of parkinsonismMovement Disorders, 1998
- Conjugate eye deviations as dyskinesias induced by levodopa in Parkinson's diseaseMovement Disorders, 1998
- Combined effects of cabergoline and L-dopa on parkinsonism in MPTP-treated cynomolgus monkeysJournal of Neural Transmission, 1996
- An appraisal of the antiparkinsonian activity of piribedil in 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine‐treated common marmosetsMovement Disorders, 1996
- Continuous lisuride effects on central dopaminergic mechanisms in Parkinson's diseaseAnnals of Neurology, 1992
- Nasogastric and intravenous infusions of (+)-4-propyl-9-hydroxynaphthoxazine (PHNO) in Parkinson's disease.Journal of Neurology, Neurosurgery & Psychiatry, 1990